Despite phenobarbital (PB) being a key component in status epilepticus (SE) treatment algorithms for decades, it has fallen out of favor compared to newer nonsedating medications due to potential for respiratory suppression and prolonged sedation. We retrospectively analyzed all nonintubated patients with refractory SE treated with parenteral PB. Forty patients were identified as having received PB in the neurologic intensive care unit at Mayo Clinic over a 7-year period through our pharmacy dispensing database. Patients who received PB for maintenance therapy, those replenishing subtherapeutic levels, those who were already intubated, and those receiving PB for a non-SE indication were excluded. Clinical data, prior treatments, therapeutic response, and outcome were reviewed. Eight patients were identified. Ages ranged from 24 to 77 years (median = 64 years); all had focal SE, and none was comatose. Seizure activity improved acutely following PB administration in seven and stopped in six. Dosages ranged from 5 to 19.8 mg/kg (median = 10.1 mg/kg); none required intubation, and one received supplemental oxygen. Patients received a median of four antiepileptic drugs prior to PB. Median interval between first drug and PB was 23.5 hours. Glasgow Coma Scale score did not change following PB administration. One patient required intervention for hypotension. Moderate-dose parenteral PB was effective in attaining seizure control in a significant proportion of noncomatose refractory SE patients. None required ventilatory support. PB dosages below those in recent guidelines may be sufficient to stop SE without clinically significant cardiopulmonary complications.
| INTRODUCTION
The treatment of refractory status epilepticus (SE) with anesthetic infusions has been associated with poor outcome and longer hospital lengths of stay. [1] [2] [3] The phenobarbital (PB) dosage used in the VA Cooperative trial 4 and recommended in the 2016 American Epilepsy Society convulsive SE guideline 5 is 15 mg/kg, whereas the dose recommended in the Neurocritical Care Society guideline is 20 mg/kg. 6 Despite being a key component in SE treatment algorithms for many years, 5 PB has fallen out of favor compared to newer nonsedating medications due to potential for respiratory suppression and prolonged sedation. We performed a retrospective review of use of subanesthetic doses of PB (dosages below those prompting need for ventilatory support) in the treatment of SE.
| MATERIALS AND METHODS
Forty consecutive patients who received parenteral PB in the neurologic intensive care unit at Mayo Clinic, Rochester, Minnesota between January 1, 2011 and December 31, 2016 were identified through our pharmacy dispensing database.
Patients were excluded if they (1) received PB for maintenance therapy (n = 15), (2) were intubated prior to administration of PB (n = 14), (3) were administered PB to raise subtherapeutic levels (n = 2), or (4) were given PB for a non-SE-related indication (n = 1). 
| RESULTS
Eight patients met the inclusion criteria. Ages ranged from 24 to 77 years (median = 64 years); three of eight (38%) were female. All had focal SE (one had epilepsia partialis continua and seven had focal nonconvulsive SE). None was comatose at initiation of treatment. Etiology of SE included subdural hemorrhage (n = 2), brain tumor (n = 2), neurodegenerative disorder (n = 1), intraparenchymal hemorrhage (n = 1), autoimmune encephalitis (n = 1), and cryptogenic (n = 1).
Patients received a median of four antiepileptic drugs prior to PB (range = 4-6). All patients received a benzodiazepine as first-line therapy (lorazepam, n = 7; midazolam, n = 1). Second-line therapy consisted of fosphenytoin (n = 5) and levetiracetam (n = 3). Third-line therapy consisted of fosphenytoin (n = 2), levetiracetam (n = 3), valproic acid (n = 1), and lacosamide (n = 2). Fourth-line therapy consisted of levetiracetam (n = 1), valproic acid (n = 4), and lacosamide (n = 2; one received PB as the fourth agent). The median interval between first drug and PB was 23.5 hours (range = 3-56 hours). Dosages ranged from 5 to 19.8 mg/kg (median = 10.1 mg/kg) and rates of infusion ranged from 6.3 to 60 mg/min (median = 23.9 mg/min). Seizure activity improved acutely following PB administration in seven, and stopped in six. Oxygen saturation dropped from a median of 97% before PB administration to a nadir of median 93% after drug infusion. No patient required intubation, and only one received supplemental oxygen. One patient developed pneumonia, but this occurred 1 week after PB administration. All but one had a decline of mean arterial pressure > 20 mm Hg, but only one required intervention. GCS did not change significantly following PB administration (median GCS = 10.5 before PB; median GCS = 9.5 after PB).
| Illustrative case 1
A 53-year-old man fell down a flight of stairs in the setting of alcohol intoxication resulting in a right-sided subdural hematoma without mass effect or shift. The hemorrhage was managed nonoperatively. On presentation he was awake and followed commands but later developed a self-limited episode of gaze preference and left arm jerking for which he was started on levetiracetam. Within hours he had two more
Key Points
• Parenteral phenobarbital at subanesthetic doses does not significantly alter cardiorespiratory function or level of consciousness • Phenobarbital dosages below those in recent guidelines may be sufficient to stop status epilepticus • Parenteral phenobarbital should be considered earlier in the algorithm for refractory focal status epilepticus with consciousness impairment focal seizures. On examination he opened eyes to voice, had a gaze preference to the right, did not fixate on the examiner or follow commands, and had occasional twitching of the left lower jaw and left arm. EEG and quantitative EEG showed highly frequent electrographic focal right centroparietal seizures. Two milligrams intravenous (IV) lorazepam and 20 mg/kg IV fosphenytoin were given without appreciable effect ( Figure 1A) . He was then loaded with 600 mg IV lacosamide, which did not lead to a significant seizure reduction, and later 3000 mg IV levetiracetam was given, leading to a temporary reduction in seizure activity ( Figure 1B) . Seizures increased again the following morning. He was loaded with 33 mg/kg IV valproic acid, which temporarily reduced his seizures, during which time he opened his eyes but did not track and followed simple commands ( Figure 1C ). He redeveloped frequent seizures later that day. Because he was not comatose, the team was hesitant to use midazolam or propofol infusions. He was given 10 mg/kg IV PB (34 hours after the initial treatment with lorazepam), which resulted in seizure control and a significant reduction in interictal discharges ( Figure 1D and 1E). The lowest oxygen saturation recorded following administration of PB was 86%, but this self-corrected without additional oxygen supplementation or airway protection. Mean arterial pressure declined following PB loading from 95 mm Hg to 68 mm Hg and recovered to the baseline after 5 hours and did not require intervention. He remained drowsy but began following commands consistently 24 hours after PB administration and did not have recurrent seizures for the final several hours of EEG monitoring. He was discharged to a rehabilitation facility.
| Illustrative case 2
A 77-year-old man with a recurrent left frontal glioma and seizures was admitted for increasing confusion. He was on 2250 mg levetiracetam twice daily in the outpatient setting. Within hours of admission, he had two witnessed secondarily generalized seizures. He received 1 mg lorazepam and was transferred to our intensive care unit. On arrival, he had a witnessed brief episode of a behavioral arrest, after which he was awake, inattentive, and disoriented. He was given 200 mg IV lacosamide. Continuous EEG monitoring was initiated, showing very frequent, mostly subclinical, focal seizures arising from the left frontotemporal region. He was loaded with 20 mg/kg IV fosphenytoin and given 2 mg IV lorazepam without significant effect. Following subsequent infusion of 2250 mg levetiracetam, there was a reduction in seizure frequency to an average of 2-3 per hour, each lasting 90-120 seconds. He was drowsy and confused. The EEG and quantitative EEG during that time period is shown in Figure 2A . After several hours, the seizure frequency again increased, and he was loaded with 19.7 mg/kg PB at 26 mg/ min (23 hours after the initial treatment with lorazepam), which resulted in seizure control ( Figure 2B and 2C) . The lowest oxygen saturation recorded following administration of PB was 93%, and there was no airway compromise. Mean arterial pressure declined following PB loading from 98 mm Hg to 61 mm Hg and recovered to baseline after 24 hours without the need for vasopressor support. Over the next 48 hours of EEG monitoring after PB administration, he was drowsy but consistently followed commands and remained seizure-free. He was ultimately discharged home.
| DISCUSSION
PB has been a mainstay of SE therapy for decades; however, it has fallen out of favor in recent years. The reasons for this are many. PB may be associated with respiratory suppression, 7, 8 and for years, SE protocols have cautioned that ventilatory support should be utilized when full loading dosages (usually specified as 15-20 mg/kg) are given. Second, PB, as shown in our series, may be associated with hypotension. This is sometimes significant enough to warrant vasopressor support, although this was not required in our cohort. Third, given its long half-life and associated potential for prolonged sedation following its use, there has long been concern that PB administration may confound clinical assessment and prognostication for a significant period of time following administration. Given these factors, the advent of several newer less-sedating parenteral antiseizure medication options with fewer cardiopulmonary risks has relegated PB to the status of a fifth-or sixth-line agent in the treatment of SE. When such treatments have failed, current practice typically progresses to utilization of a continuous infusion anesthetic medication, such as midazolam or propofol, which are titratable and have shorter half-lives and duration of sedation than PB. However, efficacy of these agents has not been established in controlled clinical trials, and their use has been associated with higher mortality and in some series poorer outcomes. 1-3 Also, these agents are not as appealing in patients with SE manifested by frequent focal seizures without coma, such as those in our study. In our cohort, PB was associated with control of seizures at subansethetic dosages. Following administration of PB, sometimes at doses considered a full loading dose, significant sedation beyond that already resulting from the seizures was not observed, ventilator support was not needed in any, and hemodynamic support was only required in one. Aggressive intravenous use of midazolam and propofol was avoided in these cases, potentially offsetting complications that have been associated with their use. One patient (12.5%) in our series developed pneumonia compared to 65%-70% of patients in other refractory SE series. 9, 10 The Physicians' Desk Reference cautions against the use of PB after benzodiazepines unless patients have This dose strategy warrants further study.
DISCLOSURE OF CONFLICTS OF INTEREST
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